BRAF and neoplasm: The MiSeq analysis also revealed that the two low-tumor-cellularity samples in which Idylla but not cobas had identified a BRAF mutation contained 4.6% V600E and 5.7% V600R, respectively, which is in line with the overall specifications of the cobas test.